PFIZER, INC.

(PFE)
  Report
Real-time Estimate Cboe BZX  -  05/20 07:53:00 am EDT
51.38 USD   +1.44%
06:28aEU Member States Seek Changes To Supply Contracts For COVID-19 Jabs Amid Declining Demand
MT
05/19US Health Agency Approves Pfizer-BioNTech's COVID-19 Booster Jab For Children
MT
05/19CDC urges Pfizer booster for children ages 5 to 11
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer CEO sees annual COVID vaccine rather than frequent boosters

01/22/2022 | 02:59pm EDT
FILE PHOTO: Children are being vaccinated against COVID-19 in Maintal near Frankfurt

JERUSALEM (Reuters) - Pfizer Inc Chief Executive Albert Bourla said on Saturday that an annual COVID-19 vaccine would be preferable to more frequent booster shots in fighting the coronavirus pandemic.

Pfizer/BioNtech's COVID-19 vaccine has shown to be effective against severe disease and death caused by the heavily-mutated Omicron variant but less effective in preventing transmission.

With cases soaring, some countries have expanded COVID-19 vaccine booster programmes or shortened the gap between shots as governments scramble to shore up protection.

In an interview with Israel's N12 News, Bourla was asked whether he sees booster shots being administered every four to five months on a regular basis.

"This will not be a good scenario. What I'm hoping (is) that we will have a vaccine that you will have to do once a year," Bourla said.

"Once a year - it is easier to convince people to do it. It is easier for people to remember.

"So from a public health perspective, it is an ideal situation. We are looking to see if we can create a vaccine that covers Omicron and doesn't forget the other variants and that could be a solution," Bourla said.

Bourla has said Pfizer could be ready to file for approval for a redesigned vaccine to fight Omicron, and mass produce it, as soon as March.

Citing three studies, the U.S. Centers for Disease Control and Prevention (CDC) said on Friday that a third dose of an mRNA vaccine is key to fighting Omicron, providing 90% protection against hospitalization.

A preliminary study published by Israel's Sheba Medical Center on Monday found that a fourth shot increases antibodies to even higher levels than the third but was likely not enoughto fend off Omicron. Nonetheless, a second booster was still advised for risk groups, Sheba said.

(Reporting by Maayan Lubell; Editing by Catherine Evans)


© Reuters 2022
All news about PFIZER, INC.
06:28aEU Member States Seek Changes To Supply Contracts For COVID-19 Jabs Amid Declining Dema..
MT
05/19US Health Agency Approves Pfizer-BioNTech's COVID-19 Booster Jab For Children
MT
05/19CDC urges Pfizer booster for children ages 5 to 11
AQ
05/19EU health regulator backs using AstraZeneca COVID shot as booster
RE
05/19Thinking about trading options or stock in Tesla, Microsoft, Walt Disney, NVIDIA, or Pf..
PR
05/19Headlands Research and Pfizer Partnership to Significantly Improve Diversity in Clinica..
CI
05/19PFIZER INC : Berenberg sticks Neutral
MD
05/18FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5..
AQ
05/18From storage to transport, hurdles to getting COVID vaccine to N.Koreans
RE
05/18China Junshi's potential COVID drug shows promise in small trial
RE
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 662 M - -
Net cash 2022 10 478 M - -
P/E ratio 2022 8,45x
Yield 2022 3,20%
Capitalization 284 B 284 B -
EV / Sales 2022 2,63x
EV / Sales 2023 3,45x
Nbr of Employees 79 000
Free-Float 58,2%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 50,65 $
Average target price 57,79 $
Spread / Average Target 14,1%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-14.23%284 192
JOHNSON & JOHNSON2.59%457 706
ABBVIE INC.12.05%268 106
ROCHE HOLDING AG-16.41%265 188
ELI LILLY AND COMPANY3.64%257 689
NOVO NORDISK A/S-0.56%236 239